Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, has just announced the upcoming 17th Annual BIO CEO Investor Conference in New York City will be featuring a presentation from the company President and Chief Executive Officer, Christopher J. Schaber, Ph.D., on Soligenix’s latest updates and strategies for 2015 and the coming years.
Among Soligenix’s presentation on its pipeline products, conference attendees can expect to learn more about the company’s oral medication SGX203, specially formulated for pediatric Crohn’s disease, a juvenile type of inflammatory bowel disease (IBD). The drug is administered in twos: one tablet releases beclomethasone dipropionate (BDP) in the upper GI tract, while the other is timed for release in the lower GI tract. As of today, the FDA has granted SGX203 Orphan Drug and Fast Track designations.
The conference will take place next week, February 9 to 10, 2015. Schaber’s presentation is scheduled on the 10th at 1:30 p.m. Eastern Standard Time in the Conrad Room at the Waldorf Astoria, New York. Now in its seventeenth year, the BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded and select private biotech companies.
Those interested can view a live webcast of the presentation, which will be uploaded for replay approximately one hour after conclusion. To watch live, visit http://www.veracast.com/webcasts/bio/ceoinvestor2015/71218189796.cfm. A replay of the presentation will be stored on the company’s investor page at http://www.soligenix.com/invest_sec.shtml after the conference.
To learn more about the BIO CEO & Investor Conference, please visit the conference website at http://www.bio.org/events/conferences/bio-ceo-investor-conference.
In other developments in IBD, a recent study from the University of Michigan led by Peter Higgins, found that compared with biologic therapy, corticosteroid therapy increases the risk in of venous thromboembolism in patients with inflammatory bowel disease five-fold. Since results showed that combination therapy with corticosteroids and biologic agents was associated with the same risk for VTE as that of corticosteroids alone, Higgins and colleagues indicate that corticosteroids seem to increase the risk for VTE occurrence. The effects of corticosteroids on this IBD associated complication should be of clinical concern and indicate the need of different treatments for patients with IBD.